In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth-a clinically relevant distinction.
Adenocarcinoma of Lung
/ chemistry
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Carcinoma in Situ
/ chemistry
Cell Proliferation
Female
Humans
Ki-67 Antigen
/ analysis
Lung Neoplasms
/ chemistry
Male
Middle Aged
Mutation
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Staging
Retrospective Studies
Tumor Suppressor Protein p53
/ analysis
Vimentin
/ analysis
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
04
10
2018
accepted:
04
03
2019
revised:
04
03
2019
pubmed:
2
4
2019
medline:
28
4
2020
entrez:
2
4
2019
Statut:
ppublish
Résumé
The switch from in situ to invasive tumor growth represents a crucial stage in the evolution of lung adenocarcinoma. However, the biological understanding of this shift is limited, and 'Noguchi Type C' tumors, being early lung adenocarcinomas with mixed in situ and invasive growth, represent those that are highly valuable in advancing our understanding of this process. All Noguchi Type C adenocarcinomas (n = 110) from the LATTICE-A cohort were reviewed and two patterns of in situ tumor growth were identified: those deemed likely to represent a true shift from precursor in situ to invasive disease ('Noguchi C1') and those in which the lepidic component appeared to represent outgrowth of the invasive tumor along existing airspaces ('Noguchi C2'). Overall Ki67 fraction was greater in C2 tumors and only C1 tumors showed significant increasing Ki67 from in situ to invasive disease. P53 positivity was acquired from in situ to invasive disease in C1 tumors but both components were positive in C2 tumors. Likewise, vimentin expression was increased from in situ to invasive tumor in C1 tumors only. Targeted next generation sequencing of 18 C1 tumors identified four mutations private to the invasive regions, including two in TP53, while 6 C2 tumors showed no private mutations. In the full LATTICe-A cohort, Ki67 fraction classified as either less than or greater than 10% within the in situ component of lung adenocarcinoma was identified as a strong predictor of patient outcome. This supports the proposition that tumors of all stages that have 'high grade' in situ components represent those with aggressive lepidic growth of the invasive clone. Overall these data support that the combined growth of Noguchi C tumors can represent two differing biological states and that 'Noguchi C1' tumors represent the genuine biological shift from in situ to invasive disease.
Identifiants
pubmed: 30932019
doi: 10.1038/s41379-019-0257-1
pii: S0893-3952(22)01027-4
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
MKI67 protein, human
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
VIM protein, human
0
Vimentin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1095-1105Subventions
Organisme : Medical Research Council
ID : MC_UP_1203/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1362/A18081
Pays : United Kingdom